Eton Pharmaceuticals Inc

ETON has pulled back into the confluence of its rising 9 and 20 EMAs near prior support, where a Bearish Exhaustion inflection signals seller fatigue and increases the probability of a reversal bounce. The medium-term uptrend remains intact with higher highs and lows supported by the 50 DMA, while RSI retracement into near-oversold territory aligns short-term timing for a rebound. We recommend initiating long positions now at the EMA support zone with focus on price acceptance above this level.

• ↑Q2 revenue climbed 99% YoY to $37.6M, driving record top-line growth.
• ↑Management upped full-year 2026 revenue forecast from $120M to >$145M.
• ↓Negative earnings yield and weak book-to-price raise valuation red flags.